Improving delivery of biologic drugs to targeted tissues using microneedle pumps
Official title: Engineering Tissue Level Targeting of Biologic Drugs via Automated Interfacial Microneedle Pumps
Funded at Georgia Institute of Technology · NIH-10893492 · Data updated 2026-11-12
This study is working on a new way to deliver important medications for conditions like diabetes, cancer, and heart disease using tiny microneedle pumps that can send the medicine right where it's needed in the body, which could lead to better treatments with fewer side effects for patients.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Georgia Institute of Technology NIH-funded |
| Lab location | 1 site (Atlanta, United States) |
| Project start | August 1, 2023 |
| Project end | June 30, 2028 |
| Funding year | 2024 |
| Award (this year) | $393,500 |
| NIH project number | 5R35GM150689-02 |
| Project ID | NIH-10893492 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients suffering from conditions that require biologic drug therapies, particularly those with cancer, heart disease, or diabetes.
✕Less likely to help
Patients who do not require biologic drug therapies or those with conditions that do not involve dense tissue targeting may not benefit from this research.
What this research studies
This research focuses on enhancing the delivery of biologic drugs, which are crucial for treating conditions like diabetes, cancer, and heart disease. The project aims to develop automated microneedle pumps that can precisely target and deliver these large molecules directly into dense tissues, such as heart muscle or tumors, where they are needed most. By improving the flow of these drugs into tissues, the research seeks to overcome the limitations of current manual injection methods that can lead to inconsistent treatment outcomes. Patients may benefit from more effective therapies with fewer side effects as a result of this innovative delivery system.
Why it matters
Potential benefit: If successful, this research could lead to more effective and targeted treatments for patients with serious conditions like cancer and heart disease.
How similar studies have gone: While the approach of using microneedle pumps for drug delivery is innovative, similar methods have shown promise in other areas of drug administration, indicating potential for success.
Where this research is happening
-
Georgia Institute of Technology
Atlanta, United States Active
Researchers
- Principal investigator: Abramson, Alex — Georgia Institute of Technology
- Study coordinator: Abramson, Alex
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.